Explore

Trendline Trendline
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA, Enhancing Access for TA-TMA Patients

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA, Enhancing Access for TA-TMA Patients

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA, Enhancing Access for TA-TMA Patients
Trendline Trendline
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA, Streamlining Access for TA-TMA Patients

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA, Streamlining Access for TA-TMA Patients

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA, Streamlining Access for TA-TMA Patients
Rapid Read Rapid Read
Federal Program Aims to Transform Rural Healthcare with $50 Billion Initiative

Federal Program Aims to Transform Rural Healthcare with $50 Billion Initiative

The Rural Health Transformation Program (RHTP) is a $50 billion federal initiative designed to transform healthcare delivery in rural America. The program shifts focus from stabilizing hospitals to redesigning entire healthcare systems. States submitted proposals to the Centers for Medicare & Medicaid Services to improve access, efficiency, and outcomes, with funding tied to performance benchmarks. The program emphasizes integrated care networks, outpatient services, and alternative delivery models. States have flexibility in designing their systems, but must meet accountability standards. The initiative aims to address systemic gaps in rural healthcare, including provider shortages and long travel distances for care.
Trendline Trendline
GSK Receives Additional Marketing Approvals for Depemokimab in Europe and China

GSK Receives Additional Marketing Approvals for Depemokimab in Europe and China

GSK Receives Additional Marketing Approvals for Depemokimab in Europe and China
Trendline Trendline
GSK Gains Additional Marketing Approval for Depemokimab with Adimab Collaboration

GSK Gains Additional Marketing Approval for Depemokimab with Adimab Collaboration

GSK Gains Additional Marketing Approval for Depemokimab with Adimab Collaboration
Trendline Trendline
LEO Pharma's ANZUPGO Cream Receives FDA Acceptance for Pediatric Eczema Treatment

LEO Pharma's ANZUPGO Cream Receives FDA Acceptance for Pediatric Eczema Treatment

LEO Pharma's ANZUPGO Cream Receives FDA Acceptance for Pediatric Eczema Treatment
Trendline Trendline
MeiraGTx Reacquires Eye Disease Gene Therapy from J Following Failed Trial

MeiraGTx Reacquires Eye Disease Gene Therapy from J Following Failed Trial

MeiraGTx Reacquires Eye Disease Gene Therapy from J Following Failed Trial
Trendline Trendline
Zealand Pharma Appoints Eric Rojas as Vice President to Strengthen Investor Relations

Zealand Pharma Appoints Eric Rojas as Vice President to Strengthen Investor Relations

Zealand Pharma Appoints Eric Rojas as Vice President to Strengthen Investor Relations
Rapid Read Rapid Read
CMS ACCESS Model Raises Concerns Over Participant Diversity and Impact on Healthcare

CMS ACCESS Model Raises Concerns Over Participant Diversity and Impact on Healthcare

The Centers for Medicare & Medicaid Services (CMS) has released a list of over 150 participants in its ACCESS model, aimed at delivering measurable clinical outcomes for patients with chronic conditions. The model includes a diverse range of organizations, from those experienced in Medicare Advantage and ACOs to newer entrants from consumer tech and analytics sectors. This diversity is intentional, as CMS seeks to encourage innovation by lowering barriers to entry. However, the mix of experience has raised concerns among industry leaders about the ability of all participants to positively influence patient outcomes. The ACCESS model requires coordination with a provider ecosystem facing financial and technological pressures, posing challenges for newer entrants.
Trendline Trendline
Khondrion Begins Phase 3 Trial for Sonlicromanol in Mitochondrial Disease

Khondrion Begins Phase 3 Trial for Sonlicromanol in Mitochondrial Disease

Khondrion Begins Phase 3 Trial for Sonlicromanol in Mitochondrial Disease
Trendline Trendline
Pangea Pharmaceuticals Launches FDA-Approved Amlodipine Powder for Oral Solution

Pangea Pharmaceuticals Launches FDA-Approved Amlodipine Powder for Oral Solution

Pangea Pharmaceuticals Launches FDA-Approved Amlodipine Powder for Oral Solution
Trendline Trendline
Alethio Therapeutics Introduces ATX-011 for Essential Thrombocythemia Treatment

Alethio Therapeutics Introduces ATX-011 for Essential Thrombocythemia Treatment

Alethio Therapeutics Introduces ATX-011 for Essential Thrombocythemia Treatment